Implementation of type 1 diabetes genetic risk screening in children in diverse communities: the Virginia PrIMeD project
Authors:
Open Access
- 14 February 2024
- journal article
- research article
- Published by Springer Nature in Genome Medicine
- Vol. 16 (1) , 1-11
Abstract
Background: Population screening for risk of type 1 diabetes (T1D) has been proposed to identify those with islet autoimmunity (presence of islet autoantibodies). As islet autoantibodies can be transient, screening with a genetic risk score has been proposed as an entry into autoantibody testing. Methods: Children were recruited from eight general pediatric and specialty clinics across Virginia with diverse community settings. Recruiters in each clinic obtained informed consent/assent, a medical history, and a saliva sample for DNA extraction in children with and without a history of T1D. A custom genotyping panel was used to define T1D genetic risk based upon associated SNPs in European- and African-genetic ancestry. Subjects at “high genetic risk” were offered a separate blood collection for screening four islet autoantibodies. A follow-up contact (email, mail, and telephone) in one half of the participants determined interest and occurrence of subsequent T1D. Results: A total of 3818 children aged 2–16 years were recruited, with 14.2% (n = 542) having a “high genetic risk.” Of children with “high genetic risk” and without pre-existing T1D (n = 494), 7.0% (34/494) consented for autoantibody screening; 82.4% (28/34) who consented also completed the blood collection, and 7.1% (2/28) of them tested positive for multiple autoantibodies. Among children with pre-existing T1D (n = 91), 52% (n = 48) had a “high genetic risk.” In the sample of children with existing T1D, there was no relationship between genetic risk and age at T1D onset. A major factor in obtaining islet autoantibody testing was concern over SARS-CoV-2 exposure. Conclusions: Minimally invasive saliva sampling implemented using a genetic risk score can identify children at genetic risk of T1D. Consent for autoantibody screening, however, was limited largely due to the SARS-CoV-2 pandemic and need for blood collection.Keywords
Funding Information
- University of Virginia (SIF88 PrIMeD)
This publication has 41 references indexed in Scilit:
- Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised, double-blind, placebo-controlled trialThe Lancet, 2011
- Robust relationship inference in genome-wide association studiesBioinformatics, 2010
- Multi-locus models of genetic risk of diseaseGenome Medicine, 2010
- Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetesNature Genetics, 2009
- Follow-Up Analysis of Genome-Wide Association Data Identifies Novel Loci for Type 1 DiabetesDiabetes, 2009
- PLINK: A Tool Set for Whole-Genome Association and Population-Based Linkage AnalysesThe American Journal of Human Genetics, 2007
- A genome-wide association study identifies KIAA0350 as a type 1 diabetes geneNature, 2007
- Clinical Characteristics of Children Diagnosed With Type 1 Diabetes Through Intensive Screening and Follow-UpDiabetes Care, 2004
- GENETIC-HETEROGENEITY OF INSULIN-DEPENDENT (TYPE-I) DIABETES-MELLITUS - EVIDENCE FROM A STUDY OF EXTENDED HAPLOTYPES1984
- HL-A ANTIGENS AND DIABETES MELLITUSThe Lancet, 1974